Belpointe Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.45M | Buy |
122,768
+3,132
| +3% | +$183K | 0.27% | 63 |
|
|
2025
Q4 | $6.45M | Buy |
119,636
+16,388
| +16% | +$788K | 0.23% | 74 |
|
|
2025
Q3 | $4.66M | Buy |
103,248
+30,833
| +43% | +$1.44M | 0.18% | 100 |
|
|
2025
Q2 | $3.35M | Sell |
72,415
-24,163
| -25% | -$1.19M | 0.14% | 128 |
|
|
2025
Q1 | $5.89M | Sell |
96,578
-91,863
| -49% | -$5.35M | 0.31% | 58 |
|
|
2024
Q4 | $9.41M | Sell |
188,441
-6,943
| -4% | -$388K | 0.57% | 26 |
|
|
2024
Q3 | $10.1M | Buy |
195,384
+5,955
| +3% | +$279K | 0.61% | 23 |
|
|
2024
Q2 | $7.87M | Buy |
189,429
+6,004
| +3% | +$269K | 0.55% | 27 |
|
|
2024
Q1 | $9.95M | Buy |
183,425
+24,803
| +16% | +$1.26M | 0.75% | 19 |
|
|
2023
Q4 | $8.14M | Sell |
158,622
-3,335
| -2% | -$175K | 0.71% | 22 |
|
|
2023
Q3 | $9.4M | Sell |
161,957
-267
| -0.2% | -$16.4K | 0.97% | 16 |
|
|
2023
Q2 | $10.4M | Buy |
162,224
+6,906
| +4% | +$463K | 1.1% | 14 |
|
|
2023
Q1 | $10.8M | Buy |
155,318
+5,030
| +3% | +$355K | 0.58% | 24 |
|
|
2022
Q4 | $10.8M | Buy |
150,288
+956
| +0.6% | +$72.1K | 0.65% | 18 |
|
|
2022
Q3 | $10.6M | Buy |
149,332
+2,290
| +2% | +$166K | 0.72% | 18 |
|
|
2022
Q2 | $11.3M | Sell |
147,042
-19,607
| -12% | -$1.49M | 0.76% | 17 |
|
|
2022
Q1 | $12.2M | Buy |
166,649
+10,519
| +7% | +$706K | 0.74% | 19 |
|
|
2021
Q4 | $9.73M | Sell |
156,130
-1,325
| -0.8% | -$77.7K | 0.61% | 23 |
|
|
2021
Q3 | $9.32M | Buy |
157,455
+3,232
| +2% | +$213K | 0.64% | 19 |
|
|
2021
Q2 | $10.3M | Sell |
154,223
-88,637
| -36% | -$5.78M | 0.74% | 19 |
|
|
2021
Q1 | $15.3M | Buy |
242,860
+31,593
| +15% | +$1.97M | 1.31% | 9 |
|
|
2020
Q4 | $13.1M | Buy |
211,267
+18,133
| +9% | +$1.11M | 1.18% | 10 |
|
|
2020
Q3 | $11.6M | Buy |
193,134
+1,439
| +0.8% | +$86.6K | 1.3% | 11 |
|
|
2020
Q2 | $11.3M | Buy |
191,695
+2,567
| +1% | +$154K | 1.46% | 10 |
|
|
2020
Q1 | $10.5M | Buy |
189,128
+15,814
| +9% | +$967K | 1.85% | 6 |
|
|
2019
Q4 | $11.1M | Buy |
173,314
+11,325
| +7% | +$649K | 1.41% | 7 |
|
|
2019
Q3 | $8.21M | Sell |
161,989
-423
| -0.3% | -$19.9K | 1.33% | 8 |
|
|
2019
Q2 | $7.37M | Sell |
162,412
-4,614
| -3% | -$215K | 1.45% | 8 |
|
|
2019
Q1 | $7.97M | Sell |
167,026
-147
| -0.1% | -$7.32K | 1.56% | 12 |
|
|
2018
Q4 | $8.69M | Sell |
167,173
-4,425
| -3% | -$238K | 2.2% | 4 |
|
|
2018
Q3 | $10.7M | Buy |
171,598
+11,766
| +7% | +$698K | 1.68% | 7 |
|
|
2018
Q2 | $8.85M | Buy |
159,832
+538
| +0.3% | +$29.1K | 2.47% | 3 |
|
|
2018
Q1 | $10.1M | Sell |
159,294
-3,438
| -2% | -$221K | 2.94% | 3 |
|
|
2017
Q4 | $9.97M | Sell |
162,732
-1,154
| -0.7% | -$72.2K | 2.18% | 4 |
|
|
2017
Q3 | $10.4M | Buy |
+163,886
| New | +$9.57M | 2.44% | 4 |
|
Other funds holding BMY
VCM
VPM
Belpointe Asset Management's BMY Position: Q1 2026 in Review
Belpointe Asset Management increased its Bristol-Myers Squibb (BMY) stake by 2.6% in Q1 2026, buying an estimated $183K and bringing the position to 122,768 shares worth $7.45M. The position accounts for 0.27% of the portfolio, ranked #63.
Belpointe Asset Management first reported a position in BMY in Q3 2017 and has held it in 35 quarters since. The position peaked at $15.3M in Q1 2021. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Belpointe Asset Management held 122,768 shares of Bristol-Myers Squibb worth $7.45M as of Q1 2026.
- Belpointe Asset Management bought 3,132 Bristol-Myers Squibb shares in Q1 2026, an estimated $183K.
- Bristol-Myers Squibb made up 0.27% of Belpointe Asset Management's portfolio in Q1 2026, its #63 holding.
- Belpointe Asset Management first reported a position in Bristol-Myers Squibb in Q3 2017 and has held it in 35 quarters since.
- Belpointe Asset Management's Bristol-Myers Squibb position peaked at $15.3M in Q1 2021.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.